Summary & Overview
HCPCS J0637: Injection, caspofungin acetate, 5 mg
HCPCS Level II code J0637 denotes the injection of caspofungin acetate, 5 mg, an intravenous antifungal agent used in treatment of invasive fungal infections. Nationally, accurate coding for antifungal agents like caspofungin matters for clinical care coordination, drug utilization monitoring, and payer reimbursement for high-cost, specialty medications. Proper use of J0637 ensures units of drug supplied are tracked consistently across sites of care.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and payer coverage context. The publication summarizes benchmarks and utilization patterns where available, highlights relevant policy considerations affecting coverage and billing of antifungal injectables, and provides clinical context for when caspofungin is billed by unit.
This resource is intended for billing professionals, pharmacy directors, revenue cycle staff, and clinicians who need a clear reference for HCPCS Level II code J0637, including its clinical purpose and how it is applied across facility-based infusion settings. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J0637 represents the injection of caspofungin acetate, 5 mg. This code denotes a single unit of the antifungal agent caspofungin supplied for intravenous administration.
Service Type: Medication administration (intravenous antifungal therapy)
Typical Site of Service: Hospital inpatient, hospital outpatient infusion center, skilled nursing facility, or other facility-based infusion settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0637 is an adult inpatient or outpatient with a serious invasive fungal infection such as candidemia or invasive candidiasis who requires intravenous echinocandin therapy. The patient often presents with fever, hemodynamic instability, or positive blood cultures for Candida species after initial empiric antibacterial therapy has failed. The clinical workflow includes: initial evaluation in the emergency department or inpatient unit, blood cultures and fungal susceptibility testing, initiation of antifungal therapy with caspofungin per infectious diseases consultation, administration of the drug by an infusion nurse or pharmacy-prepared IV dose, monitoring for infusion-related reactions and hepatic function, and daily assessment for clinical response and transition planning to oral therapy if appropriate. Typical sites of service are the hospital inpatient setting, observation unit, hospital outpatient infusion center, or an ambulatory infusion clinic for complex patients requiring monitored IV therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when services required substantially greater effort, e.g., complex dose administration with additional monitoring for severe infusion reactions. |